Why Is AC Immune (ACIU) Stock Up 45% Today?

Core Insights - AC Immune's stock is experiencing an increase following the release of its Q1 2024 earnings report, which includes a significant operational update [1] - The company has entered into a collaboration agreement with Takeda Pharmaceutical, involving a licensing agreement for AC Immune's ACI-24.060, which includes an upfront payment of $100 million and potential payments of up to$2.1 billion [1] Financial Highlights - The collaboration with Takeda Pharmaceutical includes an upfront payment of $100 million to AC Immune [1] - Potential future payments from the agreement could reach up to$2.1 billion, contingent on option exercise and milestones [1] Market Performance - AC Immune's stock has risen by 45% as of Monday morning, with over 6.6 million shares traded, significantly exceeding the average daily trading volume of approximately 185,000 shares [2] - The company is expected to report initial results from its ongoing Phase 2 clinical trial of ACI-24.060 this month, with further data anticipated in the second half of 2024 [2]